{"id":2426,"date":"2020-12-31T18:33:48","date_gmt":"2020-12-31T18:33:48","guid":{"rendered":"https:\/\/palladiumcapital.com\/?p=2426"},"modified":"2021-01-15T08:13:25","modified_gmt":"2021-01-15T08:13:25","slug":"palladium-capital-advises-merger-of-ameri-holdings-and-jay-pharma-combined-entity-to-be-called-enveric-biosciences-inc-nasdaq-envb","status":"publish","type":"post","link":"https:\/\/www.palladiumcapital.com\/palladium-capital-advises-merger-of-ameri-holdings-and-jay-pharma-combined-entity-to-be-called-enveric-biosciences-inc-nasdaq-envb\/","title":{"rendered":"Palladium Capital Advises Merger of Ameri Holdings and Jay Pharma. Combined Entity to be Called Enveric Biosciences, Inc. (NASDAQ: ENVB)"},"content":{"rendered":"

\"\"<\/a>Palladium Capital Group, LLC acted as financial advisor to the parties in connection with the following transactions.<\/p>\n

Enveric Biosciences, Inc.\u00a0<\/b>(NASDAQ:\u00a0ENVB<\/a>)\u00a0(“Enveric” or the “Company”), formerly AMERI Holdings, Inc.\u00a0<\/b>(NASDAQ:\u00a0AMRH<\/a>),\u00a0a patient-centric biotechnology company endeavoring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments with novel cannabinoid medicines, announced the completion of the previously announced spin-off of the IT services business of the Company and the tender offer, whereby the Company purchased all of the outstanding common shares of Jay Pharma Inc. (“Jay Pharma”) in exchange for shares of Company common stock, or if applicable, shares of Company preferred stock., and Jay Pharma became a wholly-owned subsidiary of the Company.<\/p>\n

The Company has also completed its name change from AMERI Holdings, Inc. to Enveric Biosciences, Inc., and has effected a 1-for-4 reverse split of its common stock, effective as of\u00a04:02 pm Eastern Time<\/span>,\u00a0December 30, 2020<\/span>. Enveric will commence trading on the Nasdaq Capital Market at the opening of trading this morning,\u00a0December 31, 2020<\/span>, under its new ticker symbol “ENVB” on a post-reverse-stock-split basis (CUSIP No. 29405E 109).<\/p>\n

“We are thrilled to complete this transaction and commence trading on the Nasdaq as Enveric Biosciences under the ticker symbol “ENVB.” Today marks the beginning of our journey as a publicly traded company, enhancing the visibility of our business to the investment community. The support of existing and new investors will enable us to continue our dedicated work of developing innovative treatments focused on the unmet need for supportive care of cancer patients by adding life to patients’ years, not just years to their lives,” said\u00a0David Johnson<\/span>, Chairman and CEO at Enveric Biosciences.<\/p>\n

Copies of the documents filed by the Company with the SEC are available free of charge on the Company’s website at or by contacting Company Investor Relations.<\/p>\n

About Enveric Biosciences\u00a0
<\/b>Enveric Biosciences is a patient-centric biotechnology company endeavoring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments. Enveric has set out with the goal of rigorously testing natural compounds, starting with cannabinoids, to provide patients and clinicians with novel prescription medicines to serve these unmet medical needs.<\/p>\n

For more information, please visit\u00a0https:\/\/www.enveric.com\/<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Palladium Capital Group, LLC acted as financial advisor to the parties in connection with the following transactions. Enveric Biosciences, Inc.\u00a0(NASDAQ:\u00a0ENVB)\u00a0(“Enveric” or the “Company”), formerly AMERI Holdings, Inc.\u00a0(NASDAQ:\u00a0AMRH),\u00a0a patient-centric biotechnology company endeavoring to enhance the lives of those who are adversely affected by the side effects of Cancer Treatments with novel cannabinoid medicines, announced the completion […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"_links":{"self":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/posts\/2426"}],"collection":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/comments?post=2426"}],"version-history":[{"count":0,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/posts\/2426\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/media?parent=2426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/categories?post=2426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.palladiumcapital.com\/wp-json\/wp\/v2\/tags?post=2426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}